Recently, GlaxoSmithKline announced that it will cut 650 jobs in the United States.
GlaxoSmithKline spokesperson Mary. Annie. Mary Anne Rhyne said the layoffs will include about 100 office workers and 450 sales representatives from Philadelphia and the North Carolina Research Triangle Park, as well as other related staff. The savings from layoffs will be used for R&D and new Commercial support for the product.
It is understood that GlaxoSmithKline has more than 30 years of history in the Research Triangle Park in North Carolina. Like Philadelphia, it is the business operation center of GlaxoSmithKline in the United States. "We are still fully committed to the research triangle garden, it is still us. The largest commercial base, this has not changed.†A GSK spokesperson said that the company still has 2,000 employees in the Research Triangle Park, and 900 production workers in Zebrun, North Carolina, were not affected by the layoffs.
According to reports, GSK has reported to the US Department of Commerce and the state on the layoffs. According to the GSK notification to the government, the actual layoffs will be carried out in the fourth quarter. According to the spokesman, after the staff is notified on Wednesday, it may take one month. Time to deal with specific details, most of the changes will be implemented in November.
According to the notice, it is finally determined that the affected employees will be notified at least 60 days before leaving the company, and can receive severance payment, COBRA health insurance subsidy and reemployment counseling support.
Since Emma Walmsley was the new CEO of GlaxoSmithKline, she has made many profound reforms in management, not only in the major changes in personnel, but also since the beginning of last year, I have replaced about 50 senior managers, including Novartis. Several executives have been introduced to companies including Google and Teva Pharmaceuticals. In addition, Walmsley also said that GSK has developed too broadly in the past, but some areas still need to be strengthened to promote the next phase of growth after 2020. Last July, she proposed that the company's strategic focus will be on respiratory diseases, HIV (AIDS), infectious diseases, and immune inflammatory diseases, while terminating or abandoning more than 30 pharmaceutical R&D projects.
Last month, GlaxoSmithKline announced its second-quarter earnings, which achieved sales of 7.3 billion pounds in the second quarter of 2018, up 4% year-on-year. Among them, the three major business consumption health products, prescription drugs and vaccines achieved sales of 1.8 billion pounds, 4.2 billion pounds and 1.3 billion pounds respectively, an increase of 3%, 1% and 16%.
According to Emma Walmsley, with the launch of new products, the development of new research and development methods, and the successful acquisition of the consumer health products business, the Group’s cost structure was evaluated and the Group’s three major businesses were fully competitive. The conditions that must be met for long-term growth and performance. Therefore, GlaxoSmithKline will launch a new major restructuring plan, which aims to improve the competitiveness and efficiency of the Group's cost structure through supply chain optimization and management cost reduction.
Starch Vegetable Empty Capsule
Starch Vegetable Empty Capsule,Empty Vegetable Capsules Size 00,Hydroxypropyl Starch Empty Capsules,Starch Empty Hard Capsules
Ningbo Jiangnan Capsule Co., Ltd. , https://www.ningbocapsule.com